New drug applications approved by US FDA as of 01- 15 February 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
In the era of Highly Active Antiretroviral Therapy (HAART), majority of the malignancies in AIDS patients are non-AIDS-defining cancers (NADC), according to an India study presented at the recently concluded European Society for Medical Oncology Asia 2018 Congress (ESMO Asia 2018).
Restoration of CD4/CD8 ratio on combination antiretroviral therapy (cART) was associated with decreased risk of Kaposi sarcoma (KS) while baseline CD8 count was related to non-Hogkin lymphoma (NHL) risk in people living with HIV (PLHIV) who had achieved viral suppression on cART, according to the COHERE* study presented at the AIDS International Conference (AIC) 2018.